Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 4/20 | 0.42 |
| ▸ | DRD2 | P14416 | 3/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5640351 | 0.90 | ALDH1A1 (0.47) | DRD4DRD2ALDH1A1SIGMAR1TMEM97 | |
| SCHEMBL5639768 | 0.90 | DRD4 (0.52) | DRD4DRD2DRD3ALDH1A1ROCK2 | |
| SCHEMBL5639886 | 0.89 | DRD4 (0.56) | OPRM1DRD4DRD2DRD3ALDH1A1 | |
| SCHEMBL5639528 | 0.88 | ROCK2 (0.46) | ALDH1A1ROCK2ROCK1CCR2 | |
| SCHEMBL5641132 | 0.84 | OPRM1 (0.53) | OPRM1DRD2ALDH1A1ROCK2ROCK1 | |
| SCHEMBL5642918 | 0.78 | ROCK1 (0.44) | ROCK2ROCK1LMNAPOLBCCR2 | |
| SCHEMBL5640699 | 0.78 | ROCK2 (0.47) | DRD4DRD2DRD3ROCK2ROCK1 | |
| SCHEMBL5640741 | 0.78 | ROCK1 (0.51) | ALDH1A1ROCK2ROCK1SIGMAR1TMEM97 | |
| SCHEMBL31587823 | 0.73 | SIGMAR1 (0.48) | DRD4DRD2DRD3ALDH1A1SIGMAR1 | |
| SCHEMBL5641849 | 0.72 | ROCK1 (0.46) | OPRM1ALDH1A1ROCK2ROCK1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217722-B2 | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20040102437-A1 | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1256574-A1 | NITROGEN-CONTAINING COMPOUNDS HAVING KINASE INHIBITORY ACTIVITY AND DRUGS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102437-A1 | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same | TNK2, ROCK1, ROCK2 | OPRM1 772/4885DRD4 3466/4885DRD2 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.